Attendee search 

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.

$3-10 million growth capital with opportunity for partial founder buy-out.

Founder / CEO

Kevin Dunworth, Founder of Celling Biosciences, has spent more than 26 years in the orthopedic industry and brings a wealth of expertise in all aspects of the business. Dunworth has run medical companies in the Middle East, Eastern and Western Europe, and the United States.

He excelled in various executive positions before founding VCD Medical, in Austin, Texas.
For the past eight years, Dunworth has successfully built a world-class distribution business, which provides a variety of orthopedic and biologic products.

Dunworth's leadership roles within the orthopedic industry have included, Director of Emerging Markets and Director of European Sales for Smith & Nephew; Director of International Sales, Vice President of Worldwide Sales and Vice President for FlouroScan International and Vice President of Sales for TransLeasing and Vice President for TransLeasing GE.

President
Steve Melchiode has extensive experience guiding businesses from start-up to profitability. After earning an undergraduate marketing degree followed by a law degree, Melchiode joined a start-up technology firm in Silicon Valley as the West Coast business development director. Melchiode's ability to build and lead successful companies, combined with his experience in medical device sales, provides him with the vision and expertise to lead the Celling Biosciences team. He brings a wide range of experience in sales, business development, marketing, finance, legal and operations management.

Melchiode began his medical device career as a sales representative with VCD Medical, learning the spinal implant industry selling Depuy Spine. After two years spent growing several new territories, Melchiode established himself in a leadership role as sales manager and by running operations for the State of Texas. For the past two years, he has worked with Kevin Dunworth to take the Celling Biosciences model from concept to market, working on business, product and partnership development as well as marketing and operations.

McDermott Will & Emery is dedicated to investing in innovation and serving the early stage life sciences community that creates new and revolutionary products and services. We understand that sophisticated legal services are necessary to help these groundbreaking individuals and organizations succeed. McDermott is proud to have created the Life Sciences Entrepreneurs Acceleration Program (LEAP) to help qualifying entrepreneurs and young companies avoid costly mistakes and chart their courses to success by providing support and affordable access to strategic legal advice. We provide these organizations with high quality legal services during the earliest stages of corporate life through engagement incentives in the form of deferred fees, discounts, fixed-fee arrangements and/or awards.

We understand that early stage life sciences clients need legal advice in such complex areas as corporate formation, financing, intellectual property, licensing and collaborations, and employee benefits. Our Life Sciences Industry Group has a deep bench of lawyers that are highly regarded in these specific practices. Our corporate lawyers have demonstrated success in advising life sciences companies on the full range of transactional legal needs, including licensing and partnering, mergers and acquisitions, venture capital, public offerings and royalty stream financing. Our intellectual property lawyers are renowned for protecting the IP rights of our clients both in and out of court. Finally, McDermott is a pioneer in the field of employee benefits and has been advising life sciences companies on various compensation strategies to both secure and maintain leadership.

Have raised $3M of a $4M round and seeking investors to complete the round.

Life Science Angels, Finney Capital and several seed investors.

Management Team

·       CEO, Gary Paul Magnant -- Serial bio-tools entrepreneur; 3 prior successful exits; formerly Sage Science, MJ Research, ThermoCeramix, Owl Scientific

·       COO/CFO, Thomas Forest Farb -- Serial healthcare-centric entrepreneur; numerous successful exits and IPOs; formerly MedicaMetrix, Indevus Pharma, Interneuron Pharma, Cytyc

·       CSO, Alan Blanchard, PhD -- Numerous commercial instrumentation successes in DNA sequencing & DNA microarrays at Agencourt Personal Genomics and Lilly

·       VP Engineering & Manufacturing, Brian Foley -- Former Head of Technology & Engineering at Merck Millipore; numerous products developed and launched

Board of Directors

·       Guy Broadbent -- Former President of Laboratory Products Division of Thermo-Fisher Scientific; former CEO of XcellerX (acquired by GE Healthcare)

·        Michael Finney, PhD -- Managing Director of Finney Capital; former Co-Founder and CSO of MJ Research; Board Member of Sage Science

In 2002, IR2Dx company founders observed that anti-diabetic therapies reduced adverse cardiology events across multiple drug classes, while at the same time, cardiovascular drugs were reducing diabetes conversions. Further, it has long been recognized that cardiovascular disease is a comorbidity of diabetes. IR2Dx founders concluded that cardiovascular disease and Type 2 diabetes are manifestations of the same underlying conditions, and by analyzing information on relevant markers, treating physicians could be provided with information to help guide drug selection and assess drug response, making improved treatment possible. The research identified pathway biomarkers that significantly elucidate the evolution, and optimal treatment, of the disease while continuing to provide glucose control, throughout the treatment process with a patient. These biomarkers are: high-sensitivity C-reactive protein (hsCRP), intact proinsulin, insulin, adiponectin and C-peptide. Through the IR2Dx patented methods and systems of evaluating the baseline and subsequent levels of these markers, the physician is given a previously unavailable, cost effective window into the pathways and causes of his/her patient’s specific disease, with the opportunity to intervene therapeutically before the disease state progresses further. Specifically, the IR2Dx platform, for the first time in diabetes, provides physicians with easily accessible clinical information to aid in: • Assessment of the current state of a patient’s metabolic pathways; • Determination of the likely further progression of disease; and, • Determination of optimal treatment strategies for the patient.

To date, the IR2Dx diagnostic panel markers have been used prospectively on over 14,000 patients across 35 clinical trials, with over 40 publications. These studies validated the use of the panel markers, and covered patients at all stages of disease including prediabetes, across the range of anti-diabetic drug- classes. These studies demonstrated improvements in group mean HbA1c levels, the present standard for clinical success in the diabetes field.

$12 million, can be staged to support commercial laboratory rollout and kit development ($5 million), and further clinical studies ($7 million).

At commercialization

Friends & Family, Founders, Physicians

Patents issued in US and Europe

Highly Experienced Team. CEO has over 40 years in the diagnostics field (including 17 years at Abbott Diagnostics), and all management team members have over 30 years in biotech. Many of our key advisors are well recognized world leaders in diagnostics, diabetes and cancer.

In contrast to most studies that focus on the unhealthy cancer patient populations, BIOARRAY studies cancer in reverse by using genes in healthy cell organization to identify cancer markers. These biomarkers work like surveillance cameras watching how a particular breast cancer will behave when treated with chemotherapy. By measuring the mRNA expression levels of these biomarkers, Bioarray diagnostic tests significantly increase the accuracy of predicted chemo-response rates.

BIOARRAY's lead test distinguishes itself by addressing a vital question at the beginning of basic chemotherapeutic treatment for 75% of diagnosed breast cancer patients who currently have a 24% response rate. BIOARRAY's test clinical proof of concept studies showed:

55% reduction in ineffective chemo

68% improvement in response rate

42% of patients classified as non-responders up front

The company is raising its Series A round of financing to achieve key milestones to take the lead test to early adoption.

BIOARRAY has developed a business plan whereas the Bioarray diagnostic uses commercially-available gene-expression platforms such as PCR for its lab analysis. BIOARRAY will engage licensees and distributors to access the global market. BIOARRAY will hold closely the proprietary algorithms at the heart of the diagnostic in a cloud-based information platform. BIOARRAY's lead test is in a position to go to market within 2 years.

Grant: Avon Foundation – first of its kind from Avon

Equity: Connecticut Innovations and Angels

BIOARRAY intellectual property includes methods, algorithms and biomarkers. BIOARRAY strategy to protect its intellectual property is a combination of trade secrets and patents. The company is growing a patent portfolio of US and international patents that is exclusively owned by BIOARRAY and is not subject to licensing or royalty obligations.

1. Performed clinical proof of concept with I-SPY 1 clinical trial
2. Data gathered (and ready to complete analysis) for I-SPY 2 trial
3. Built cloud-based interactive information platform and interactive portal
4. Built laboratory infrastructure
5. Developed IP strategy comprising know-how and patents (internationally filed)

CEO Marcia Fournier has over a decade of experience in oncology at leading Institutions in the US. Non-executive chairman Michal Preminger and Board Directors Una Ryan and Henry Kay have extensive experience in management, financing, acquisitions, and diagnostics. The Company also has a team of active business advisors with experience in business development, acquisitions and venture capital.